Entrada Therapeutics, Inc. business relationships
Companies named in Entrada Therapeutics, Inc.’s 10-K filed 2026-02-26, and public companies whose annual reports name Entrada Therapeutics, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.7 / 10
- AI naming
- 5 / 100 Top 3% in its category
- Agent readiness
- 0 / 100
- AI adoption
- 0 / 100
Layers: Peptides
Named in Entrada Therapeutics, Inc.’s annual report 2
“Strategic Collaboration and License Agreement, dated December 7, 2022, by and between the Registrant and Vertex Pharmaceuticals Incorporated, as amended by Amendment No. 1 on October 26, 2023 (incorporated by reference to Exhibit 10.16 to the Annual Report on Form 10-K filed by the Registrant on Mar...” SEC filing
“In addition, our VX-670 partnership with Vertex Pharmaceuticals Incorporated ("Vertex") continues to progress, with dosing completion anticipated in mid-2026.” SEC filing
Companies whose annual reports name Entrada Therapeutics, Inc. 2
“• Entrada Therapeutics, Inc. In 2022, we established a collaboration with Entrada focused on enabling efficient” SEC filing
“VX-670, an endosomal escape vehicle technology with a CUG steric blocker oligonucleotide by Entrada Therapeutics, Inc. in collaboration with Vertex Pharmaceuticals Incorporated, or Vertex, being evaluated in a Phase 1/2 clinical trial in Canada, the United Kingdom, the European Union and Australia;...” SEC filing
Links are read automatically from public company filings, so every link carries the sentence it came from.
Not investment advice. Scores, rankings and connections are automated estimates from public sources, provided as is. Connections are read automatically from public company filings and may be incomplete or wrong. To correct or remove a company page or a connection, email [email protected]. Company names and logos belong to their owners. Showing them does not mean the company endorses Engagemii or that Engagemii endorses it. Terms